dsm-firmenich and Lallemand partner to launch early life synbiotic solutions

Published: 25-Apr-2024

The solution will contain a combination of human milk oligosaccharides (HMOs) that will mimic breast milk, boosting the infant immune system and gut microbiome

dsm-firmenich, an ingredients company specialising in the nutrition, health and beauty sphere and Lallemand Health Solutions, a business focusing on the development of probiotics, has partnered to launch a novel synergistic synbiotic solution for early life nutrition. 

The new solutions are a combination of human milk oligosaccharides (HMOs) from dsm-firmenich and probiotics from Lallemand Health Solutions, which could provide potential synergistic benefits that support infant health and development. 

These solutions aim to support a microbiome establishment closer to that of breast-fed infants and the development of the immune system, the gut microbiome and optimal developmental trajectories.

Promising research has highlighted the ability of certain HMOs to selectively promote the growth of certain probiotic strains, as well as enhancing the production of useful metabolites in promoting gut health, natural defence, cognition, growth and development.2 

These new synbiotic solutions harness this synergistic combination to help bring the composition and functionality of infant formula closer to that of breast milk – the gold standard for infant nutrition.

"All infants deserve the best start in life, and access to optimum nutrition during early life is essential. Developing synbiotic solutions that aim to narrow the gap in outcomes between breastfed and non-breastfed infants could be a game changer." Says James Young, Vice President Early Life Nutrition at dsm-firmenich.


You may also like